| Literature DB >> 18455276 |
Joseph P Shott1, Shannon M McGrath, Maria Grazia Pau, Jerome H V Custers, Olga Ophorst, Marie-Ange Demoitié, Marie-Claude Dubois, Jack Komisar, Michelle Cobb, Kent E Kester, Patrice Dubois, Joe Cohen, Jaap Goudsmit, D Gray Heppner, V Ann Stewart.
Abstract
Falciparum malaria vaccine candidates have been developed using recombinant, replication-deficient serotype 5 and 35 adenoviruses (Ad5, Ad35) encoding the Plasmodium falciparum circumsporozoite surface protein (CSP) (Ad5.CS, Ad35.CS) (Crucell Holland BV, Leiden, The Netherlands). To evaluate the immunogenicity of these constructs, BALB/cJ mice were immunized twice with either Ad5.CS, Ad35.CS, empty Ad5-vector (eAd5), empty Ad35 vector (eAd35), or saline. Another group received the CSP-based RTS,S malaria vaccine formulated in the proprietary Adjuvant System AS01B (GlaxoSmithKline Biologicals, Rixensart, Belgium). Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18455276 DOI: 10.1016/j.vaccine.2008.03.080
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641